Literature DB >> 23709362

Management of chronic depressive patients with residual symptoms.

Changsu Han1, Tzung Lieh Yeh, Masaki Kato, Soichiro Sato, Chia-Ming Chang, Chi-Un Pae.   

Abstract

Various clinical issues are involved in the appropriate diagnosis and proper treatment interventions for patients with major depressive disorder (MDD). Despite a number of diverse antidepressants for treating MDD now, response and remission rates following adequate trials of antidepressant intervention are still not satisfactory. Furthermore, a significant proportion of MDD patients have residual symptoms, which are associated with increased relapse and recurrence of MDD, leading to negative impacts on the clinical course and outcomes of MDD. Timely and appropriate decision-making regarding the proper management of such cases is required in our routine daily practice. These issues are illustrated and also framed by one MDD case with a complicated clinical course. This review paper may give physicians clinical insight into how we can effectively and properly evaluate and manage such patients in clinical practice.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23709362     DOI: 10.1007/s40263-012-0034-x

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  28 in total

1.  Residual symptoms in depressed patients who respond acutely to fluoxetine.

Authors:  A A Nierenberg; B R Keefe; V C Leslie; J E Alpert; J A Pava; J J Worthington; J F Rosenbaum; M Fava
Journal:  J Clin Psychiatry       Date:  1999-04       Impact factor: 4.384

2.  A description of next-step switching versus augmentation practices for outpatients with treatment-resistant major depressive disorder enrolled in an academic specialty clinic.

Authors:  George I Papakostas; Timothy J Petersen; Cassandra Green; Dan V Iosifescu; Albert S Yeung; Andrew A Nierenberg; Maurizio Fava; Michael A Posternak
Journal:  Ann Clin Psychiatry       Date:  2005 Jul-Sep       Impact factor: 1.567

3.  Development of a rating scale for primary depressive illness.

Authors:  M Hamilton
Journal:  Br J Soc Clin Psychol       Date:  1967-12

4.  The PHQ-9: validity of a brief depression severity measure.

Authors:  K Kroenke; R L Spitzer; J B Williams
Journal:  J Gen Intern Med       Date:  2001-09       Impact factor: 5.128

5.  Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.

Authors:  A John Rush; Madhukar H Trivedi; Stephen R Wisniewski; Andrew A Nierenberg; Jonathan W Stewart; Diane Warden; George Niederehe; Michael E Thase; Philip W Lavori; Barry D Lebowitz; Patrick J McGrath; Jerrold F Rosenbaum; Harold A Sackeim; David J Kupfer; James Luther; Maurizio Fava
Journal:  Am J Psychiatry       Date:  2006-11       Impact factor: 18.112

6.  Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants.

Authors:  Robert M Berman; Maurizio Fava; Michael E Thase; Madhukar H Trivedi; René Swanink; Robert D McQuade; William H Carson; David Adson; Leslie Taylor; James Hazel; Ronald N Marcus
Journal:  CNS Spectr       Date:  2009-04       Impact factor: 3.790

Review 7.  Outcomes in major depressive disorder: the evolving concept of remission and its implications for treatment.

Authors:  Hans-Jürgen Möller
Journal:  World J Biol Psychiatry       Date:  2008       Impact factor: 4.132

8.  Diagnostic validity and added value of the Geriatric Depression Scale for depression in primary care: a meta-analysis of GDS30 and GDS15.

Authors:  Alex J Mitchell; Vicky Bird; Maria Rizzo; Nick Meader
Journal:  J Affect Disord       Date:  2009-10-02       Impact factor: 4.839

9.  Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report.

Authors:  A A Nierenberg; M M Husain; M H Trivedi; M Fava; D Warden; S R Wisniewski; S Miyahara; A J Rush
Journal:  Psychol Med       Date:  2009-05-22       Impact factor: 7.723

10.  Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder.

Authors:  Robert M Berman; Michael E Thase; Madhukar H Trivedi; James A Hazel; Sabrina Vogel Marler; Robert D McQuade; William Carson; Ross A Baker; Ronald N Marcus
Journal:  Neuropsychiatr Dis Treat       Date:  2011-05-24       Impact factor: 2.570

View more
  5 in total

1.  Expression of the 5-HT1A serotonin receptor in the hippocampus is required for social stress resilience and the antidepressant-like effects induced by the nicotinic partial agonist cytisine.

Authors:  Yann S Mineur; Emily B Einstein; Matthew P Bentham; Mattis B Wigestrand; Sam Blakeman; Sylvia A Newbold; Marina R Picciotto
Journal:  Neuropsychopharmacology       Date:  2014-10-07       Impact factor: 7.853

2.  Reduced Slc6a15 in Nucleus Accumbens D2-Neurons Underlies Stress Susceptibility.

Authors:  Ramesh Chandra; T Chase Francis; Hyungwoo Nam; Lace M Riggs; Michel Engeln; Sarah Rudzinskas; Prasad Konkalmatt; Scott J Russo; Gustavo Turecki; Sergio D Iniguez; Mary Kay Lobo
Journal:  J Neurosci       Date:  2017-06-02       Impact factor: 6.167

3.  Qualitative Research on Fatigue Associated with Depression: Content Validity of the Fatigue Associated with Depression Questionnaire (FAsD-V2).

Authors:  Louis S Matza; Lindsey T Murray; Glenn A Phillips; Thomas J Konechnik; Ellen B Dennehy; Elizabeth N Bush; Dennis A Revicki
Journal:  Patient       Date:  2015-10       Impact factor: 3.883

4.  A Pharmacogenomic-based Antidepressant Treatment for Patients with Major Depressive Disorder: Results from an 8-week, Randomized, Single-blinded Clinical Trial.

Authors:  Changsu Han; Sheng-Min Wang; Won-Myong Bahk; Soo-Jung Lee; Ashwin A Patkar; Prakash S Masand; Laura Mandelli; Chi-Un Pae; Alessandro Serretti
Journal:  Clin Psychopharmacol Neurosci       Date:  2018-11-30       Impact factor: 2.582

Review 5.  Optimizing the Use of Aripiprazole Augmentation in the Treatment of Major Depressive Disorder: From Clinical Trials to Clinical Practice.

Authors:  Changsu Han; Sheng-Min Wang; Soo-Jung Lee; Tae-Youn Jun; Chi-Un Pae
Journal:  Chonnam Med J       Date:  2015-08-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.